In prostate cancer, Ipsen et al. (2022) determined that deletion of PARP1, ARH3 (ADP-ribosylserine hydrolase), tryptophan 5-monooxygenase activation protein epsilon, and ubiquitin protein ligase E3 component n-recognin 5 resulted in olaparib resistance, where PARP1 or ARH3 knockdown resulted in reduced autophagy and increased cellular resistance, suggesting that low ARH3 expression is an independent prognostic indicator. Here, ADPRS is linked to prostate cancer.